Whitehawk Therapeutics Inc 2025年季度报告

FORM10-Q______________________________________ (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedMarch 31, 2025OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ______________ to ______________Commission File Number:001-38560______________________________________ WHITEHAWK THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)______________________________________ Delaware (551)321-2234(Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report)______________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.YesxNooIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YesxNooIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNox As of May2, 2025, the registrant had47,109,293shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PagePART I.FINANCIAL INFORMATION2Item 1.Condensed Consolidated Financial Statements2Condensed Consolidated Balance Sheets – March 31, 2025 and December 31, 2024 (Unaudited)2Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) – Three MonthsEnded March 31, 2025 and 2024 (Unaudited)3Condensed Consolidated Statements of Stockholders’ Equity– Three Months Ended March 31, 2025 and2024 (Unaudited)4Condensed Consolidated Statements of Cash Flows – Three Months Ended March 31, 2025 and 2024(Unaudited)4Notes to Condensed Consolidated Financial Statements (Unaudited)6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures About Market Risk36Item 4.Controls and Procedures36PART II.OTHER INFORMATION37Item 1.Legal Proceedings37Item 1A.Risk Factors37Item 2.Unregistered Sales of Equity Securities and Use of Proceeds97Item 3.Defaults Upon Senior Securities97Item 4.Mine Safety Disclosures97Item 5.Other Information97Item 6.Exhibits98Signatures100 PART I—FINANCIAL INFORMATION WHITEHAWK THERAPEUTICS, INC. Condensed Consolidated Balance Sheets(In thousands, except share data and par value)(Unaudited) WHITEHAWK THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)(In thousands, except share data and earnings per share amounts)(Unaudited) WHITEHAWK THERAPEUTICS, INC. Condensed Consolidated Statements ofStockholders’ Equity(In thousands, including share amounts)(Unaudited) WHITEHAWK THERAPEUTICS, INC. Condensed Consolidated Statements of Cash Flows(In thousands)(Unaudited) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED) 1.Nature of Organization and Operations Whitehawk Therapeutics, Inc. (the "Company") is an oncology therapeutics company applying advanced technologies to establishedtumor biology that are intended to efficiently deliver improved cancer treatments. The Company has a deep experience in chemistry,formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, and taking productcandidates from the clinic to approval, launch, and commercialization. Current ADC Business On December 19, 2024, the Company entered into an intellectual property license agreement (the “WuXi License Agreement”) withWuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of threenext generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in highpotential cancer indications with significant unmet need. Refer to Note 12 for